Compass Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Compass Therapeutics Stock-Based Compensation Growth & History (CMPX)
Compass Therapeutics's stock-based compensation was $8.4M for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.4M | −$192,000 | −2.24% |
| 2024 | 2024-12-31 | $8.6M | $2.4M | +39.87% |
| 2023 | 2023-12-31 | $6.1M | $790,000 | +14.82% |
| 2022 | 2022-12-31 | $5.3M | $1.3M | +32.29% |
| 2021 | 2021-12-31 | $4.0M | $13,000 | +0.32% |
| 2020 · Dec 31 | 2020-12-31 | $4.0M | $3.1M | +338.91% |
| 2019 · Dec 31 | 2019-12-31 | $915,000 | — | — |
Compass Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q4.20
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.8M | $2.0M | +72.77% |
| Q1 2026 | 2026-03-31 | $5.1M | $2.6M | +101.79% |
| Q4 2025 | 2025-12-31 | $1.8M | −$413,000 | −18.45% |
| Q3 2025 | 2025-09-30 | $1.2M | −$960,000 | −43.68% |
| Q2 2025 | 2025-06-30 | $2.8M | $670,000 | +31.59% |
| Q1 2025 | 2025-03-31 | $2.5M | $511,000 | +25.51% |
| Q4 2024 | 2024-12-31 | $2.2M | $638,000 | +39.88% |
| Q3 2024 | 2024-09-30 | $2.2M | $573,000 | +35.26% |
| Q2 2024 | 2024-06-30 | $2.1M | $493,000 | +30.28% |
| Q1 2024 | 2024-03-31 | $2.0M | $736,000 | +58.09% |
| Q4 2023 | 2023-12-31 | $1.6M | $575,000 | +56.10% |
| Q3 2023 | 2023-09-30 | $1.6M | $338,000 | +26.26% |
| Q2 2023 | 2023-06-30 | $1.6M | $184,000 | +12.74% |
| Q1 2023 | 2023-03-31 | $1.3M | −$307,000 | −19.50% |
| Q4 2022 | 2022-12-31 | $1.0M | — | — |
| Q3 2022 | 2022-09-30 | $1.3M | $300,000 | +30.40% |
| Q2 2022 | 2022-06-30 | $1.4M | — | — |
| Q1 2022 | 2022-03-31 | $1.6M | $626,000 | +66.03% |
| Q3 2021 | 2021-09-30 | $987,000 | −$1.5M | −61.08% |
| Q2 2021 · Jun 30 | 2021-06-30 | $0 | −$183,000 | — |
| Q2 2021 · Jun 20 | 2021-06-20 | $908,000 | $725,000 | +396.17% |
| Q1 2021 · Mar 31 | 2021-03-31 | $948,000 | $701,000 | +283.81% |
| Q4 2020 | 2020-12-31 | $1.1M | — | — |
| Q2 2021 · Sep 30 | 2020-09-30 | $2.5M | $2.3M | +918.47% |
| Q1 2021 · Jun 30 | 2020-06-30 | $183,000 | −$2,000 | −1.08% |
| Q4 2020 | 2020-03-31 | $247,000 | — | — |
| Q2 2020 | 2019-09-30 | $249,000 | — | — |
| Q1 2020 | 2019-06-30 | $185,000 | — | — |
Compass Therapeutics stock-based compensation trends
Over the last five fiscal years, Compass Therapeutics's stock-based compensation increased from $4.0M to $8.4M, a change of $4.4M. The latest reported quarter, Q2 2026, shows $4.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗